H.C. Wainwright analyst Sean Lee lowered the firm’s price target on Casi Pharmaceuticals (CASI) to $4 from $6 and keeps a Buy rating on the shares. The firm expects the divestment of the company’s Chinese business to occur before the end of Q3.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals: Strategic Divestment and CID-103 Potential Drive Buy Rating
- CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics
- CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations
- CASI Pharmaceuticals receives proposal to acquire China business for $20M
- CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments